(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.
Upstream Bio's earnings in 2026 is -$156,500,000.On average, 9 Wall Street analysts forecast UPB's earnings for 2026 to be -$160,659,895, with the lowest UPB earnings forecast at -$175,196,129, and the highest UPB earnings forecast at -$124,795,817. On average, 7 Wall Street analysts forecast UPB's earnings for 2027 to be -$164,274,783, with the lowest UPB earnings forecast at -$185,608,104, and the highest UPB earnings forecast at -$132,847,160.
In 2028, UPB is forecast to generate -$177,239,089 in earnings, with the lowest earnings forecast at -$214,165,725 and the highest earnings forecast at -$145,499,270.